NEW YORK – Synthetic biology firm Telesis Bio said Wednesday that it has entered into a private stock purchase agreement to raise up to $21 million.

纽约——合成生物学公司 Telesis Bio 周三表示，已达成一项私人股票购买协议，筹集高达 2100 万美元的资金。

The financing was led by Novalis LifeSciences and Northpond Ventures. Telesis Bio said it plans to use the money raised to accelerate adoption of its recently launched Gibson SOLA technology for enzymatic DNA and mRNA synthesis.

本轮融资由诺瓦利斯生命科学公司和北极星创投领投。特莱西斯生物表示，计划利用这笔资金加速推广其最近推出的用于酶促DNA和mRNA合成的吉布森SOLA技术。

Through the purchase agreement, Telesis Bio said it will issue and sell shares of a new series of convertible preferred stock in a private placement through two closings. The initial tranche includes the sale and issuance of approximately $17 million in shares of convertible stock, of which $8 million was tied to cash infusion and $9 million related to conversion of outstanding debt into convertible stock, according to the company..

通过购买协议，Telesis Bio表示将通过两轮交割，在私募中发行并出售新系列的可转换优先股。公司称，初始部分包括约1700万美元的可转换股票的出售和发行，其中800万美元与现金注入相关，900万美元涉及将未偿债务转换为可转换股票。

The second tranche is expected to include the sale and issuance of $4 million in shares of convertible preferred stock, subject to the company board's approval. The firm said it expects the second tranche to close on or before March 6, 2026.

第二部分预计包括出售和发行400万美元的可转换优先股，但需经公司董事会批准。该公司表示，预计第二部分将在2026年3月6日或之前完成。

As a condition to the private placement, the holders of the company’s redeemable convertible preferred stock consented to convert their securities into common stock, and certain holders of warrants exercisable for the company’s securities consented to terminate such warrants.

作为私募的条件，公司可赎回可转换优先股的持有人同意将其证券转换为普通股，且公司证券的某些认股权证持有人同意终止这些认股权证。

“This financing gives us a strong balance sheet with no debt and sufficient capital to reach cash-flow breakeven while continuing to serve existing customers and expanding adoption of this next-generation platform,” Telesis Bio President and CEO Eric Esser said in a statement.

“这笔融资使我们拥有强劲的资产负债表，无债务且资本充足，足以实现现金流盈亏平衡，同时继续服务现有客户并扩大这一下一代平台的采用，”Telesis Bio总裁兼首席执行官埃里克·埃瑟在一份声明中表示。

Based in San Diego, Telesis Bio, formerly known as

总部位于圣地亚哥的 Telesis Bio，原名为

Codex DNA

DNA法典

, previously developed a proprietary enzymatic DNA synthesis method called short oligo ligation assembly enzymatic DNA synthesis (SOLA EDS). The method leverages Gibson assembly, an enzymatic method pioneered by Chief Technology Officer Dan Gibson.

，之前开发了一种名为短寡核苷酸连接组装酶促DNA合成（SOLA EDS）的专有酶促DNA合成方法。该方法利用了首席技术官丹·吉布森开创的酶促方法——吉布森组装。